- Home
- ATRA vs NRXS Comparison
ATRA vs NRXS Comparison
Compare ATRA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATRA | NRXS |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.2M | 82.0M |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ATRA | NRXS |
|---|---|---|
| Price | $8.59 | $6.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $13.67 | $11.00 |
| AVG Volume (30 Days) | 20.3K | ★ 137.7K |
| Earning Date | 11-16-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,772,000.00 | $3,569,282.00 |
| Revenue This Year | N/A | $132.54 |
| Revenue Next Year | $1,334.59 | $138.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $3.92 | $2.21 |
| 52 Week High | $19.15 | $9.33 |
Technical Indicators
Market Signals| Indicator | ATRA | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 42.08 |
| Support Level | $7.72 | $6.60 |
| Resistance Level | $9.93 | $7.79 |
| Average True Range (ATR) | 0.57 | 0.46 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 21.26 | 36.59 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).